Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Amortization (2016 - 2025)

ProQR Therapeutics' Amortization history spans 6 years, with the latest figure at $1169.1 for Q3 2025.

  • On a quarterly basis, Amortization rose 6.45% to $1169.1 in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.9 million, a 51.6% decrease, with the full-year FY2024 number at $1068.6, down 0.68% from a year prior.
  • Amortization hit $1169.1 in Q3 2025 for ProQR Therapeutics, up from $1132.0 in the prior quarter.
  • Over the last five years, Amortization for PRQR hit a ceiling of $1179.3 in Q3 2021 and a floor of -$20.9 million in Q4 2021.
  • Historically, Amortization has averaged -$6.5 million across 5 years, with a median of -$2.9 million in 2024.
  • The widest YoY moves for Amortization: up 100.04% in 2025, down 1011935.35% in 2025.
  • Tracing PRQR's Amortization over 5 years: stood at -$20.9 million in 2021, then soared by 100.0% to $1020.2 in 2022, then grew by 5.46% to $1075.9 in 2023, then fell by 0.68% to $1068.6 in 2024, then increased by 9.4% to $1169.1 in 2025.
  • Business Quant data shows Amortization for PRQR at $1169.1 in Q3 2025, $1132.0 in Q2 2025, and -$11.0 million in Q1 2025.